Direct comparison
Protocol Amendment vs. Administrative Change
How ICH E6(R2) and FDA rules distinguish a protocol amendment (needs IRB/regulator review) from a minor administrative change that doesn't.
Ask about Protocol Amendment vs. Administrative Change
Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.
Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this
How do Protocol Amendment, Administrative Change compare side by side?
The table below compares Protocol Amendment, Administrative Change across 7 procurement-relevant dimensions, from regulatory basis through documentation trail.
Side-by-side comparison
| Dimension | Protocol Amendment | Administrative Change |
|---|---|---|
| Regulatory basis | ICH E6(R2) Sec. 1.60 (definition) and Sec. 4.5.2 (implementation rule); 21 CFR 312.30 for IND-regulated FDA notification | ICH E6(R2) Sec. 4.5.2's narrow exception for 'logistical or administrative aspects' |
| What triggers it | A change that could affect participant safety, participant rights/welfare, or the scientific integrity/validity of the trial | A purely operational or clerical edit with no plausible effect on safety, rights, or scientific integrity |
| Typical examples | Eligibility criteria, dosing/schedule, primary/secondary endpoints, consent language, safety monitoring, statistical analysis plan, new site/investigator | Change of monitor, monitor's phone number, typo correction, sponsor contact-info update, document formatting |
| IRB/IEC review required before implementation? | Yes -- full board or, for genuinely minor amendments, expedited review under 45 CFR 46.110 / 21 CFR 56.110, but documented approval is required before the change takes effect | No prior approval required to implement, though most IRBs still expect documentation/notification of the change |
| FDA notification (IND-regulated drug trials) | Required under 21 CFR 312.30 when the change significantly affects subject safety (Phase 1) or safety/scope/scientific quality (Phase 2/3) | Not submitted as a protocol amendment; unrelated informational updates may go to FDA separately as an information amendment under 21 CFR 312.31 |
| Who classifies it | Proposed by the sponsor, but the IRB/IEC makes the binding classification determination | Proposed by the sponsor; IRB can still reclassify it as an amendment if it disagrees with the 'administrative only' label |
| Documentation trail | Amendment document, IRB approval letter, and (for IND trials) the FDA submission cover letter/tracking | Change log, notification memo, or update noted at next continuing review |
Common questions
Common questions about Protocol Amendment vs Administrative Change
Does an administrative change need to be reported to the IRB at all?
+
Usually yes, even though it doesn't require prior-approval review the way a substantive amendment does -- most IRBs still want the change documented, often via simple notification or at the next continuing review, so the record stays current.
Who decides whether a proposed change is an amendment or merely administrative?
+
The sponsor typically proposes the classification when submitting the change, but the IRB/IEC makes the final determination for anything routed through it. A sponsor can't unilaterally label a change 'administrative only' and skip review if the IRB would classify it as substantive.
Can an administrative change turn out to actually be a protocol amendment?
+
Yes. If a seemingly minor edit turns out to affect eligibility, safety monitoring, or study conduct, it should be reclassified and routed through amendment review rather than implemented as a simple administrative update.
Does this distinction apply the same way outside the US?
+
The underlying ICH E6 logic -- substantive changes need prospective ethics-committee review, purely operational ones don't -- is shared internationally, but exact mechanics differ by jurisdiction. The EU Clinical Trials Regulation (536/2014) uses its own defined term, 'substantial modification,' with its own notification procedure through the EU Clinical Trials Information System, rather than mapping directly onto this FDA/ICH terminology.
Going deeper
